Case study topics | Overall time lag in years from “discovery” to implementation (ie not always counting some initial discovery time) | Field: cardiovascular disease (CVD) or mental health (MH) | Intervention type | Lag from “discovery” to start of first phase I trial or human research | Lag from phase I to start of first phase II trial | Lag from phase II to start of first phase III trial | Lag from start of phase III or human research to first research review and synthesis | Lag from research review and synthesis to first policy statement | Lag from policy statement to implementation |
---|---|---|---|---|---|---|---|---|---|
1: Amlodipine | 23 years | CVD | Pharmaceutical | 3 | 1 | 2 | 10 | 7 | 0 |
2: Olanzapine | 20 years | MH | Pharmaceutical | 4 | 2 | 5 | 5 | 4 | 0 |
3: Abdominal aortic aneurysm screening | 26 years | CVD | Screening | 0 | 1 | 5 | 14 | 5 | 1 |
4a: Smoking reduction: Evidence on passive smoking to widespread bans | 39 years | CVD | Public health | 14 | n/a | n/a | 5 | 19 | 1 |
4b: Smoking reduction: Link between smoking and ill health to ban on advertising (Top TV ban, Bottom widespread ban) | 26 years | CVD | Public health | 12 | n/a | n/a | 6 | 8 | 0 |
54 years | 30 | 6 | |||||||
5: Cognitive behavioural therapy and depression | 49 years | MH | Psychosocial | 15 | n/a | n/a | 12 | 12 | 10 |
6: Cognitive behavioural therapy and schizophrenia | 48 years | MH | Psychosocial | 17 | n/a | n/a | 23 | 0 | 8 |
7: Early intervention for schizophrenia | 18 years | MH | Service configuration/Health service delivery | 6 | n/a | n/a | Reviews after implementation | 7 | 5 |